1. Home
  2. ALLO vs BCML Comparison

ALLO vs BCML Comparison

Compare ALLO & BCML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • BCML
  • Stock Information
  • Founded
  • ALLO 2017
  • BCML 2004
  • Country
  • ALLO United States
  • BCML United States
  • Employees
  • ALLO N/A
  • BCML N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • BCML Major Banks
  • Sector
  • ALLO Health Care
  • BCML Finance
  • Exchange
  • ALLO Nasdaq
  • BCML Nasdaq
  • Market Cap
  • ALLO 338.9M
  • BCML 279.0M
  • IPO Year
  • ALLO 2018
  • BCML N/A
  • Fundamental
  • Price
  • ALLO $1.55
  • BCML $26.00
  • Analyst Decision
  • ALLO Strong Buy
  • BCML
  • Analyst Count
  • ALLO 10
  • BCML 0
  • Target Price
  • ALLO $9.66
  • BCML N/A
  • AVG Volume (30 Days)
  • ALLO 2.6M
  • BCML 29.6K
  • Earning Date
  • ALLO 05-12-2025
  • BCML 04-17-2025
  • Dividend Yield
  • ALLO N/A
  • BCML 2.31%
  • EPS Growth
  • ALLO N/A
  • BCML N/A
  • EPS
  • ALLO N/A
  • BCML 2.10
  • Revenue
  • ALLO $22,000.00
  • BCML $95,714,000.00
  • Revenue This Year
  • ALLO N/A
  • BCML $3.69
  • Revenue Next Year
  • ALLO $9.07
  • BCML $6.03
  • P/E Ratio
  • ALLO N/A
  • BCML $12.36
  • Revenue Growth
  • ALLO N/A
  • BCML N/A
  • 52 Week Low
  • ALLO $1.23
  • BCML $18.54
  • 52 Week High
  • ALLO $3.78
  • BCML $30.13
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 49.84
  • BCML 53.31
  • Support Level
  • ALLO $1.38
  • BCML $25.11
  • Resistance Level
  • ALLO $1.75
  • BCML $27.56
  • Average True Range (ATR)
  • ALLO 0.13
  • BCML 1.37
  • MACD
  • ALLO 0.04
  • BCML 0.21
  • Stochastic Oscillator
  • ALLO 61.54
  • BCML 72.66

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About BCML BayCom Corp

BayCom Corp is a bank holding company for United Business Bank. It provides a broad range of financial services to businesses and business owners as well as individuals through its full-service branches and loan production office. The company targets its services to small and medium-sized businesses, professional firms, real estate professionals, nonprofit businesses, labor unions, and related nonprofit entities and businesses and individual consumers. Its products and services include deposit products, personal accounts, loans, online banking, cash management, and business savings services.

Share on Social Networks: